We present guidelines from the Immunochemistry group of the Spanish Society for Immunology that are designed to provide a practical tool for the diagnosis and follow-up of monoclonal gammopathies. We review the clinical and analytical features of various monoclonal gammopathies, international consensus guidelines and techniques used to detect and follow-up monoclonal components.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.rce.2015.09.002DOI Listing

Publication Analysis

Top Keywords

monoclonal gammopathies
12
diagnosis follow-up
8
follow-up monoclonal
8
laboratory guidelines
4
guidelines diagnosis
4
follow-up patients
4
monoclonal
4
patients monoclonal
4
gammopathies guidelines
4
guidelines immunochemistry
4

Similar Publications

Enhancing staging in multiple myeloma using an m6A regulatory gene-pairing model.

Clin Exp Med

January 2025

Department of Hematology, The Second Xiangya Hospital, Central South University, Changsha, 410011, Hunan, People's Republic of China.

Multiple myeloma (MM) is characterized by clonal plasma cell proliferation in the bone marrow, challenging prognosis prediction. We developed a gene-pairing prognostic risk model using m6A regulatory genes and a nested LASSO method. A cutoff of - 0.

View Article and Find Full Text PDF

Multiple myeloma is a prevalent hematologic cancer. This investigation analyzes the latest global, regional, and national data from the Global Burden of Diseases, Injuries, and Risk Factors Study 2021. Data on the incidence, prevalence, disability-adjusted life years, and mortality rates of multiple myeloma, including estimates and 95% uncertainty intervals, were sourced from the 2021 Global Burden of Diseases Study.

View Article and Find Full Text PDF

Introduction: Immunoglobulin D (IgD) myeloma is a rare subtype often described as aggressive with advanced disease at diagnosis. Primary renal involvement is seen in scarce cases.

Observation: This case features a 55-year-old man with IgD lambda myeloma presenting severe renal failure at diagnosis.

View Article and Find Full Text PDF

Decreased STING predicts adverse efficacy in bortezomib regimens and poor survival in multiple myeloma.

Clin Exp Med

January 2025

Stem Cell Immunity and Regeneration Key Laboratory of Luzhou, The Affiliated Hospital, Southwest Medical University, Luzhou, Sichuan, China.

Purpose: STING (stimulator of interferon genes) is involved in viral and bacterial defense through interferon pathway and innate immunity. Increased susceptibility to infection is a common manifestation of multiple myeloma (MM). Thus, we aimed to explore the clinical significance and possible mechanism of STING in MM.

View Article and Find Full Text PDF

Oral vancomycin induced flushing syndrome in a multiple myeloma patient: A case report and review of the literature.

Medicine (Baltimore)

November 2024

Department of Clinical Pharmacy, Shanghai General Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.

Background: Patients with hematological malignancies are at high-risk of Clostridium difficile infection (CDI). Oral vancomycin is a first-line treatment for CDI. Vancomycin has been widely reported to induce flushing syndrome (also known as Red man syndrome), a well-known hypersensitivity reaction mostly occurs after intravenous administration.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!